Anteris Technologies focused on commercialising DurAVR™ 3D single piece aortic valve
Paradigm Biopharmaceuticals completes Zilosul dosing under FDA’s Expanded Access Program
Pharmaxis anti-fibrotic pipeline review highlights drug with strong pre-clinical data for bone marrow cancer myelofibrosis
Only registered members can use this feature.
Copyright © Proactive Investors 2019.
All Rights Reserved - Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.